Clinical Trials Logo

Clinical Trial Summary

This is a phase Ib/II trial to evaluate the safety, pharmacokinetics and preliminary efficacy of QL1706 or QL1604 combined with bevacizumab in patients with advanced hepatocellular carcinoma.


Clinical Trial Description

This is an open, multicenter phase Ib/II trial of QL1706 or QL1604 combined with bevacizumabin patients with advanced hepatocellular carcinoma to evaluate the safety, PK characteristics and preliminary efficacy. This trial is divided into three cohorts, Cohort A, Cohort B and Cohort C. Cohort A was the dose exploration phase of the study, with 2 dose groups designed, QL1706 5mg/kg q3w + bevacizumab 7.5mg/kg q3w group and QL1706 5mg/kg q3w + bevacizumab 15mg/kg q3w group, to explore the safe dose of bevacizumab. After approximately 20 cases are enrolled in the bevacizumab safety dose group identified in Cohort A, enrollment will be initiated in Cohort B. Cohort B will be QL1604 200 mg fixed dose q3w + bevacizumab safety dose, and random enrollment will be used for both Cohort A and Cohort B. The decision to initiate a cohort C study will be based on the preliminary results of the efficacy analysis of cohort A and cohort B. If a Cohort C study is initiated, the Cohort C dosing regimen will be QL1706 7.5 mg/kg q3w + bevacizumab safe dose q3w. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05603039
Study type Interventional
Source Qilu Pharmaceutical Co., Ltd.
Contact Feng Professor Bi
Phone 028-85423203
Email bifenggcp@163.com
Status Recruiting
Phase Phase 1/Phase 2
Start date July 1, 2021
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT01754987 - A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective Phase 1/Phase 2
Recruiting NCT05698459 - OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer Phase 1
Recruiting NCT03146637 - Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer Phase 2
Withdrawn NCT03484962 - Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer Phase 2
Recruiting NCT04906434 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor Phase 1
Recruiting NCT04163237 - Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer Phase 3
Recruiting NCT02873442 - Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer Phase 1/Phase 2
Recruiting NCT02862613 - Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer Phase 1/Phase 2
Recruiting NCT03474822 - Plasmodium Immunotherapy for Breast and Liver Cancers Phase 1/Phase 2